drugset
drugset / Trial / NCT00426660

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660 ↗

Phase 3 Completed 1047 enrolled ViiV Healthcare
Non-randomizedTreatment

Summary

To provide access to maraviroc to patients who have limited or no therapeutic treatment options and to collect more safety data in a broader patient population.

Timeline

Start
2007-02
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Maraviroc Other / unclassified 150 mg —
Subject Maraviroc Other / unclassified 300 mg —
Subject Maraviroc Other / unclassified 600 mg —

Indications

HIV infectious disease